The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•1 May 2026•

1 min read

Incyte Receives FDA Approval for Jakafi XR Extended-Release Tablets

Key Facts

1The U.S. FDA approved Jakafi XR extended-release tablets for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.

Incyte has announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR (ruxolitinib) extended-release tablets for several key indications. The approval covers the treatment of myelofibrosis, polycythemia vera, and chronic graft-versus-host disease. This new once-daily dosing regimen offers a significant improvement in convenience for patients who previously relied on immediate-release formulations. As a major regulatory milestone, this approval is expected to support long-term revenue stability for the large-cap biotech firm. The expansion of the Jakafi product line reinforces Incyte's competitive position within the chronic blood and bone marrow disorder market. Market analysts view this development as a positive driver for the company's growth trajectory in the healthcare sector.